新景智源

NeoXing is a biotechnology company headquartered in Suzhou, China, specializing in the development of next-generation T-cell receptor engineered T-cell (TCR-T) therapies. The company utilizes a proprietary high-throughput platform to identify high-affinity, high-specificity TCRs and their corresponding neoantigens for the treatment of solid tumors. By integrating computational biology with experimental validation, NeoXing aims to overcome the challenges of the immunosuppressive tumor microenvironment. Their pipeline includes several programs targeting both shared antigens and personalized neoantigens in indications such as lung and liver cancer. The company has successfully raised significant funding from prominent investors like Matrix Partners China and Qiming Venture Partners to advance its candidates toward clinical trials. NeoXing's approach represents a precision medicine strategy designed to provide potent and durable responses in cancer patients.